Buxton Martin J, Lacey Loretto A, Feagan Brian G, Niecko Timothy, Miller David W, Townsend Raymond J
Health Economics Research Group, Brunel University, Uxbridge, Middlesex, UK.
Value Health. 2007 May-Jun;10(3):214-20. doi: 10.1111/j.1524-4733.2007.00171.x.
To examine the relationship between the Inflammatory Bowel Disease Questionnaire (IBDQ), Crohn's Disease Activity Index (CDAI) and measures of utility (EQ-5D and the SF-6D indexes), and to estimate algorithms to map the two utility values from IBDQ and CDAI scores.
A large data set from clinical trials in Crohn's disease provided contemporaneous patient responses to all four questionnaires. Paired observations from multiple time-points were analyzed. We calculated mean utility scores by IBDQ and CDAI score deciles; Spearman correlation coefficients for paired observations between IBDQ and EQ-5D (n = 3320) and IBDQ and SF-6D (n = 3230), and explored regression models using maximum likelihood estimation. The IBDQ/SF-6D model was validated against paired observations from an independent data set.
The IBDQ decile analysis demonstrated a consistent positive relationship with both utility indexes. Correlations between the IBDQ and both the EQ-5D and SF-6D were statistically significant (P < 0.0001), with correlation coefficients of 0.76 and 0.85, respectively. A simple linear model between EQ-5D and IBDQ explained 45% of the variance. The residuals plot for the IBDQ/SF-6D model suggested some nonlinearity and a nonlinear model explained 69% of the variance. In the validation analysis, no statistically significant difference was observed between the mean observed SF-6D and the SF-6D scores estimated using the IBDQ/SF-6D regression model.
Given the strength, consistency, and predictable characteristics of the relationships, the algorithms appear to provide valuable and valid methods to estimate utilities from IBDQ scores (but not CDAI) in trials of Crohn's disease patients that have collected IBDQ scores but not utilities.
研究炎症性肠病问卷(IBDQ)、克罗恩病活动指数(CDAI)与效用测量指标(EQ - 5D和SF - 6D指数)之间的关系,并估计从IBDQ和CDAI分数映射两个效用值的算法。
来自克罗恩病临床试验的一个大型数据集提供了患者对所有四份问卷的同期回答。对多个时间点的配对观察结果进行了分析。我们按IBDQ和CDAI分数十分位数计算平均效用分数;计算IBDQ与EQ - 5D(n = 3320)以及IBDQ与SF - 6D(n = 3230)配对观察结果的斯皮尔曼相关系数,并使用最大似然估计探索回归模型。IBDQ/SF - 6D模型根据独立数据集的配对观察结果进行了验证。
IBDQ十分位数分析表明其与两个效用指数均存在一致的正相关关系。IBDQ与EQ - 5D和SF - 6D之间的相关性均具有统计学意义(P < 0.0001),相关系数分别为0.76和0.85。EQ - 5D与IBDQ之间的简单线性模型解释了45%的方差。IBDQ/SF - 6D模型的残差图显示存在一些非线性,一个非线性模型解释了69%的方差。在验证分析中,观察到的平均SF - 6D与使用IBDQ/SF - 6D回归模型估计的SF - 6D分数之间没有统计学上的显著差异。
鉴于这些关系的强度、一致性和可预测特征,在已收集IBDQ分数但未收集效用数据的克罗恩病患者试验中,这些算法似乎提供了从IBDQ分数(而非CDAI)估计效用的有价值且有效的方法。